NO20081127L - Vaksinering mot Dengue virusinfeksjon - Google Patents

Vaksinering mot Dengue virusinfeksjon

Info

Publication number
NO20081127L
NO20081127L NO20081127A NO20081127A NO20081127L NO 20081127 L NO20081127 L NO 20081127L NO 20081127 A NO20081127 A NO 20081127A NO 20081127 A NO20081127 A NO 20081127A NO 20081127 L NO20081127 L NO 20081127L
Authority
NO
Norway
Prior art keywords
virus infection
dengue virus
vaccination against
against dengue
vaccination
Prior art date
Application number
NO20081127A
Other languages
English (en)
Inventor
Thomas P Monath
Jean Lang
Farshad Guirakhoo
Niranjan Kanesa-Thasan
Thomas H Ermak
Remi Forrat
Original Assignee
Sanofi Pasteur Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Sa filed Critical Sanofi Pasteur Sa
Publication of NO20081127L publication Critical patent/NO20081127L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår fremgangsmåter og kit for anvendelse ved vaksinering mot dengue virusinfeksjon.
NO20081127A 2005-08-10 2008-03-04 Vaksinering mot Dengue virusinfeksjon NO20081127L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70703805P 2005-08-10 2005-08-10
US71944805P 2005-09-22 2005-09-22
PCT/US2006/030846 WO2007021672A2 (en) 2005-08-10 2006-08-09 Vaccination against dengue virus infection

Publications (1)

Publication Number Publication Date
NO20081127L true NO20081127L (no) 2008-05-07

Family

ID=37758084

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081127A NO20081127L (no) 2005-08-10 2008-03-04 Vaksinering mot Dengue virusinfeksjon

Country Status (12)

Country Link
US (1) US20080193477A1 (no)
EP (1) EP1924280A4 (no)
JP (1) JP5227172B2 (no)
AR (1) AR055603A1 (no)
AU (1) AU2006280144B2 (no)
BR (1) BRPI0614265A2 (no)
CA (1) CA2618783A1 (no)
IL (1) IL189329A (no)
MY (1) MY151051A (no)
NO (1) NO20081127L (no)
TW (1) TW200740458A (no)
WO (1) WO2007021672A2 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
EP2438198A4 (en) * 2009-06-01 2014-05-14 Inviragen Inc COMPOSITIONS AND METHODS FOR THE DELIVERY OF VACCINES AGAINST DENGUE VIRUS
BRPI0904020B8 (pt) 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
WO2013151764A1 (en) 2012-04-02 2013-10-10 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus epitopes
MX2015000446A (es) 2012-07-24 2015-03-12 Sanofi Pasteur Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue.
WO2014016360A1 (en) 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
EP2931310A4 (en) * 2012-12-14 2016-05-25 Takeda Vaccines Inc COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS
CN105451763B (zh) 2013-03-15 2021-06-18 武田疫苗股份有限公司 用于疫苗中的登革热病毒嵌合式构建物的组合物及方法
CA2938495A1 (en) * 2014-02-11 2015-08-20 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody
GB201704126D0 (en) * 2017-03-15 2017-04-26 Blom Nihlén Kim Andrea Vaccine
US20200392468A1 (en) * 2017-03-30 2020-12-17 Merck Sharp & Dohme Corp. Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids
WO2019069130A1 (en) 2017-10-05 2019-04-11 Sanofi Pasteur COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE
CA3111332A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
MX2022001742A (es) 2019-08-16 2022-04-07 Takeda Vaccines Inc Metodos para prevenir el dengue y la hepatitis a.
WO2021174059A1 (en) 2020-02-27 2021-09-02 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US6676936B1 (en) * 1988-07-14 2004-01-13 The United States Of America As Represented By The Department Of Health And Human Services. Chimeric and/or growth-restricted flaviviruses
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
US7192593B2 (en) * 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
WO2001039802A1 (en) * 1999-12-01 2001-06-07 Oravax, Inc. Chimeric flavivirus vaccines
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
US6966281B1 (en) * 2004-05-05 2005-11-22 Hale James R Internal combustion device and methods of use
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Also Published As

Publication number Publication date
JP5227172B2 (ja) 2013-07-03
AU2006280144A1 (en) 2007-02-22
IL189329A (en) 2015-07-30
TW200740458A (en) 2007-11-01
IL189329A0 (en) 2008-06-05
MY151051A (en) 2014-03-31
WO2007021672A2 (en) 2007-02-22
AR055603A1 (es) 2007-08-29
JP2009504654A (ja) 2009-02-05
EP1924280A4 (en) 2008-12-10
US20080193477A1 (en) 2008-08-14
BRPI0614265A2 (pt) 2011-03-22
WO2007021672A3 (en) 2007-11-22
AU2006280144B2 (en) 2012-06-14
EP1924280A2 (en) 2008-05-28
CA2618783A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
NO20081127L (no) Vaksinering mot Dengue virusinfeksjon
CY2018013I2 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DK1844155T3 (da) Sekvensspecifikke serinrekombinaser og fremgangsmåder til anvendelse deraf
DE602005014463D1 (de) Vielzweckverfahren zur herstellung von elastischen laminaten
DK2302055T3 (da) Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler
DK1954140T3 (da) Glycerollevulinatketaler og deres anvendelse
DE602006005211D1 (de) HARQ-Verfahren und -System
ES2422556T3 (es) Tratamiento de hepatitis vírica
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
EA201001322A1 (ru) Вакцины против хламидиоза
BRPI0819819A2 (pt) Preparações, método e kits ùteis para o tratamento de tosse
DK1968631T3 (da) Vaccine
DK1765327T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DE602005013523D1 (de) Blockanordnung zur Aufnahme von Stossenergien
DK1896571T3 (da) Materialer og fremgangsmåder, der vedrører cellebaserede behandlinger
DK1937276T3 (da) Forbedret testosterongel og fremgangsmåde til anvendelse deraf
BRPI0607474A2 (pt) vacinação enriquecida com glicosido-alquila
NO20091181L (no) Anti-C5AR-antistoffer med forbedrede egenskaper
DE602004016894D1 (de) Umschlagsdeformation mittels unterteilten Oberflächen
ITMI20041216A1 (it) Sega curva
DE502006000635D1 (de) Abgasbehandlungseinrichtung
DE602005007582D1 (de) In biologischen proben
NO20084599L (no) Sammensetninger, fremgangsmater og kit ved anvendelse av adenosin og inosin i kombinasjon for diagnose og behandling
NO343767B1 (no) Håndholdt hudfjerner
WO2007081365A3 (en) Multiple antigenic agents and methods for using the same

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application